Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1893-1895

  Fountzilas, G ^a   Athanassiadis, A ^a   Kalogera Fountzila, A ^a   Aravantinos, G ^b   Bafaloukos, D ^c   Briasoulis, E ^d   Dombros, N ^a   Loannidis, I ^a   Pavlidis, N ^d   Kosmidis, P ^c   Skarlos, D ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Breast cancer; Carboplatin; Chemotherapy; Paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIMETINDENE; MITOXANTRONE; ONDANSETRON; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

EID: 0031406339     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00217-7     Document Type: Article

References (15)

1. Rowinsky EK, Donehower RC. Drug therapy: Paclitaxel (taxol). N Engl J Med 1995, 332, 1004-1014.
2. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 1995, 13, 1152-1159.
3. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicinrefractory or mitoxantrone-refractory breast cancer: A phase I-II trial of 96-hour infusion. J Clin Oncol 1994, 12, 1621-1629.
4. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995, 87, 1169-1175.
5. Fountzilas G, Athanassiades A, Giannakakis T, et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. EurJ Cancer 1996, 32A, 47-51.
6. Gelmon KA. Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin Oncol 1995, 22 (Suppl. 12), 117-122.
7. O'Brien MER, Talbot DC, Simth IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993, 11, 2112-2117.
8. Fountzilas G, Athanassiadis A, Samantas E, et al. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. Semin Oncol 1997 24 (Suppl. 2), 66-67.
9. Miller AB, Hoogsraten B, Staquet M, et al Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
10. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
11. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334, 1-6.
12. Wasserheit C, Frazein A, Oratz R, et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer. An active regimen with limiting neurotoxicity. J Clin Oncol 1996, 14, 1993-1999.
13. Aravantinos G, Skarlos DV, Kosmidis P, et al. A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. Eur J Cancer 1997, 33, 160-163.
14. Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Naû Inst Monogr 1993, 15, 63-67.
15. Kosmidis P, Mylonakis N, Fountzilas G, et al. Paclitaxel and carboplatin in non-operable non-small cell lung cancer. Semin Oncol 1996, 23 (Suppl. 15), 16-18.